GlassScriptPhysician profile
Deborah D Beyer
NPI 1316987654
$11,370.01
in general payments reported to CMS, 2019-2025
38 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $1,293 · 2021: $1,514 · 2022: $1,875 · 2023: $1,699 · 2024: $1,978 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,050.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,711.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,383.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,160.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,138.14 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $1,084.25 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $970.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $283.18 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $277.56 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $226.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.51 | 2021-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $183.93 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $183.35 | 2022 | |
| Exact Sciences Corporation | $166.46 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $157.20 | 2019-2021 | |
| Allergan, INC. | $143.98 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.